Page 6 - Sergio Traversa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

United statesCoral gablesUniversity of miami coral gablesSouth koreaJohn hixonEli lillySergio traversaTim mccarthyReliance clinical research programRelmada therapeutics incLilly research laboratoriesPrnewswire relmada therapeutics incDepauw universitySecurities exchangeCompany continues commercial preparationsTrial readouts

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Eli lillyGino santiniSergio traversaTim mccarthyReliance clinical research programCompany phaseCorporate development strategic advisorRelmada therapeutics incPrnewswire relmada therapeutics incTherapeutics incSecurities exchangeKetamine related compounds international hybrid conferenceBusiness developmentCorporate development strategicRelated compounds international hybrid conferenceChief executive

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

United statesSergio traversaTim mccarthyRelmada therapeutics incClinical research programCompany phaseMeeting of the american college neuropsychopharmacologySecurities exchangeRelmada therapeuticsChief executiveAmerican journalAnnual meetingAmerican collegeAnticipated milestonesResearch programPrivate securities litigation reform act

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events

/PRNewswire/ Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Maged shenoudaTim mccarthySergio traversaNeedham companyRelmada therapeutics incClinical research programSecurities exchangeNeuroscience forumRelmada therapeuticsChief executive officerChief financial officerAnnual neuroscience forumAnnual healthcare conferenceResearch programPrivate securities litigation reform actSecurities act

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Paolo manfrediJack henningfieldTim mccarthylifesciSergio traversaRelmada therapeutics incClinical research programDiversion control divisionClinical pharmacology research branchSecurities exchangeAbuse liability at pinney associatesRelmada therapeuticsDrug likingChief scientific officerNew drug applicationVice presidentHealth policy